Counterpoint: Because some surrogate end point biomarkers measure the neoplastic process they will have high utility in the development of cancer chemopreventive agents against sporadic cancers

Cancer Epidemiology Biomarkers and Prevention

Volumn 12, Issue 7, 2003, Pages 593-596

  Kelloff, Gary J ^a   O'Shaughnessy, Joyce A ^b   Gordon, Gary B ^c   Hawk, Ernest T ^a   Sigman, Caroline C ^d  

^a NATIONAL CANCER INSTITUTE   (United States)

^b BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^c ABBOTT LABORATORIES   (United States)

^d CCS Associates   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CELECOXIB; CHOLESTEROL; IMATINIB;

CANCER; CANCER PREVENTION; CARCINOGENESIS; CARDIOVASCULAR RISK; CHEMOPROPHYLAXIS; DISEASE MARKER; DRUG TARGETING; MORPHOLOGY; NON INVASIVE MEASUREMENT; PHENOTYPE; PRIORITY JOURNAL; PROBABILITY; REVIEW; RISK FACTOR; STOCHASTIC MODEL; VALIDATION PROCESS;

ANTICARCINOGENIC AGENTS; CLINICAL TRIALS, PHASE II; DRUG APPROVAL; DRUG DESIGN; HUMANS; NEOPLASMS; NEOPLASTIC PROCESSES; PHENOTYPE; PRECANCEROUS CONDITIONS; PREDICTIVE VALUE OF TESTS; REPRODUCIBILITY OF RESULTS; TUMOR MARKERS, BIOLOGICAL;

EID: 0041345977     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (35)

1. Armstrong, W. B., Taylor, T. H., and Meyskens, F. L., Jr. Commentary: as surrogate endpoint biomarkers are likely to be limited/limiting in their usefulness in the development of cancer chemoprevention agents against sporadic cancers. Cancer Epidemiol. Biomark. Prev., 12, 2003.
2. Steinbach, G., Lynch, P. M., Phillips, R. K., Wallace, M. H., Hawk, E., Gordon, G. B., Wakabayashi, N., Saunders, B., Shen, Y., Fujimura, T., Su, L. K., Levin, B., Godio, L., Patterson, S., Rodriguez-Bigas, M. A., Jester, S. L., King, K. L., Schumacher, M. A., Abbruzzese, J., DuBois, R. N., Hittelman, W. N., Zimmerman, S., Sherman, J. W., and Kelloff, G. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med., 342: 1946-1952, 2000.
3. U.S. Food & Drug Administration. Solaraze (diclofenac sodium) gel, USPI. October 20, 2000.
4. Theracys, BCG Live (Intravesical). Physicians' Desk Reference, 55th ed, pp. 792-794. Montvale, NJ: Medical Economics Company, 2001.
5. Dinehart, S. M. The treatment of actinic keratoses. J. Am. Acad. Dermatol., 42: 25-28, 2000.
6. Fisher, B., Dignam, J., Wolmark, N., Wickerham, D. L., Fisher, E. R., Mamounas, E., Smith, R., Begovic, M., Dimitrov, N. V., Margolese, R. G., Kardinal, C. G., Kavanah, M. T., Fehrenbacher, L., and Oishi, R. H. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet, 353: 1993-2000, 1999.
7. Fisher, B., Land, S., Mamounas, E., Dignam, J., Fisher, E. R., and Wolmark, N. Prevention of invasive breast cancer in women with ductal carcinoma in situ: an update of the national surgical adjuvant breast and bowel project experience. Semin. Oncol., 28: 400-418, 2001.
8. Kelloff, G. J., Sigman, C. C., Johnson, K. M., Boone, C. W., Greenwald, P., Crowell, J. A., Hawk, E. T., and Doody, L. A. Perspectives on surrogate end points in the development of drugs that reduce the risk of cancer. Cancer Epidemiol. Biomark. Prev., 9: 127-137, 2000.
9. O'Shaughnessy, J. A., Kelloff, G. J., Gordon, G. B., Dannenberg, A. J., Hong, W. K., Fabian, C. J., Sigman, C. C., Bertagnolli, M. M., Stratton, S. P., Lam, S., Nelson, W. G., Meyskens, F. L., Alberts, D. S., Follen, M., Rustgi, A. K., Papadimitrakopoulou, V., Scardino, P. T., Gazdar, A. F., Wattenberg, L. W., Sporn, M. B., Sakr, W. A., Lippman, S. M., and Von Hoff, D. D. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin. Cancer Res., 8: 314-346, 2002.
10. Lipkin, M., Levin, B., Kim, Y. S., and Kelloff, G. J. (eds.) Intermediate Biomarkers of Precancer and Their Application in Chemoprevention. J. Cell. Biochem., Suppl. 16G, New York, NY: Wiley-Liss, 1992.
11. Boone, C. W., and Kelloff, G. J. (eds.) Quantitative Pathology in Chemoprevention Trials: Standardization and Quality Control of Surrogate Endpoint Biomarker Assays for Colon, Breast and Prostate. J. Cell. Biochem., Suppl. 19, New York, NY: Wiley-Liss, 1994.
12. Kelloff, G. J., and Boone, C. W. (eds.) Prospects for Chemoprevention in Cohorts with Cancer Risk Markers. J. Cell. Biochem., Suppl. 25, New York, NY: Wiley-Liss, 1996.
13. Greenberg, E. R., and Hong, W. K. Cancer prevention: biomarkers and surrogate endpoints in clinical trials. In: Downing, G. J. (ed.) Biomarkers and Surrogate Endpoints: Clinical Research and Applications. New York, NY: Elsevier, 2000, pp. 217-232.
14. Metz, D. C., and Alberts, D. A. Gastrointestinal cancer prevention in the United States: the road ahead. Cancer Epidemiol. Biomark. Prev., 12: 81-83, 2003.
15. Black, D. L. Protein diversity from alternative splicing: a challenge for bioinformatics and post-genome biology. Cell, 103: 367-370, 2000.
16. Petricoin, E. F., Zoon, K. C., Kohn, E. C., Barrett, J. C., and Liotta, L. A. Clinical proteomics: translating benchside promise into bedside reality. Nat. Rev. Drug Disc., 1: 683-695, 2002.
17. Grandori, C., Cowley, S. M., James, L. P., and Eisenman, R. N. The Myc/Max/Mad network and the transcriptional control of cell behavior. Annu. Rev. Cell Dev. Biol., 16: 653-699, 2000.
18. Hanahan, D., and Weinberg, R. A. The hallmarks of cancer. Cell, 100: 57-70, 2000.
19. Ilyas, M., Straub, J., Tomlinson, I. P., and Bodmer, W. F. Genetic pathways in colorectal and other cancers. Eur. J. Cancer, 35: 1986-2002, 1999.
20. Califano, J., van der Riet, P., Westra, W., Nawroz, H., Clayman, G., Piantadosi, S., Corio, R., Lee, D., Greenberg, B., Koch, W., and Sidransky, D. Genetic progression model for head and neck cancer: implications for field cancerization. Cancer Res., 56: 2488-2492, 1996.
21. Califano, J., Westra, W. H., Meininger, G., Corio, R., Koch, W. M., and Sidransky, D. Genetic progression and clonal relationship of recurrent premalignant head and neck lesions. Clin. Cancer Res., 6: 347-352, 2000.
22. Sudbø, J., Kildal, W., Risberg, B., Koppang, H. S., Danielsen, H. E., and Reith, A. DNA content as a prognostic marker in patients with oral leukoplakia. N. Engl. J. Med., 344: 1270-1278, 2001.
23. Chen, Y., Yakhini, Z., Ben-Dor, A., Dougherty, E., Trent, J. M., and Bittner, M. Analysis of expression patterns: the scope of the problem, the problem of scope. Dis. Markers, 17: 59-65, 2001.
24. Foulds, L. Multiple etiologic factors in neoplastic development. Cancer Res., 25: 1339-1347, 1965.
25. Gould, A. L., Rossouw, J. E., Santanello, N. C., Heyse, J. F., and Furberg, C. D. Cholesterol reduction yields clinical benefit. A new look at old data. Circulation, 91: 2274-2282, 1995.
26. Weissleder, R., and Mahmood, U. Molecular imaging. Radiology, 219: 316-333, 2001.
27. Gambhir, S. S. Molecular imaging of cancer with positron emission tomography. Nat. Rev. Cancer, 2: 683-693, 2002.
28. US Food & Drug Administration. Gleevec package insert. May 11, 2001.
29. O'Brien, S. G., Guilhot, F., Larson, R. A., Gathmann, I., Baccarani, M. Cervantes, F., Corenelissen, J. J., Fischer, T., Hochhaus, A. Hughes, T., Lechner, K., Nielsen, J. L., Rousselot, P., Reiffers, J., Saglio, G., Shepherd, J., Simonsson, B., Gratwohl, A., Goldman, J. M., Kantarjian, H., Taylor, K., Verhoef, G., Bolton, A. E., Capdeville, R., and Druker, B. J. for the IRIS Investigators. Imantinib compared with interferon and low-dose cytarabine for newly diagnosed chrnoic-phase chronic myeloid leukemia. N. Engl. J. Med., 348: 994-1004, 2003.
30. Peggs, K., and Mackinnon, S. Imatinib mesylate - the new gold standard for treatment of chronic myeloid leukemia. N. Engl. J. Med., 348: 1048-1050, 2003.
31. Wong, I. H., and Lo, Y. M. New markers for cancer detection. Curr. Oncol. Rep., 4: 471-477, 2002.
32. Petricoin, E. F., III, Ornstein, D. K., Paweletz, C. P., Ardekani, A., Hackett, P. S., Hitt, B. A., Velassco, A., Trucco, C., Wiegand, L., Wood, K., Simone, C. B., Levine, P. J., Linehan, W. M., Emmert-Buck, M. R., Steinberg, S. M., Kohn, E. C., and Liotta, L. A. Serum proteomic patterns for detection of prostate cancer. J. Natl. Cancer Inst., 94: 1576-1578, 2002.
33. Rosenwald, A., and Staudt, L. M. Clinical translation of gene expression profiling in lymphomas and leukemias. Semin. Oncol., 29: 258-263, 2002.
34. Belhocine, T., Steinmetz, N., Hustinx, R., Bartsch, P., Jerusalem, G., Seidel, L., Rigo, P., and Green, A. Increased uptake of the apoptosis-imaging agent (99m)Tc recombinant human Annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin. Cancer Res., 8: 2766-2774, 2002.
35. Blankenberg, F. To scan or not to scan, it is a question of timing: technetium-99m-annexin v radionuclide imaging assessment of treatment efficacy after one course of chemotherapy. Clin. Cancer Res., 8: 2757-2758, 2002.